“…koreana, C. saxicola, S. adoxoides, T. officinale, C. coronarium, G. inflate, and L. japonica are commonly employed ethnopharmacological agents used for the treatment of inflammatory diseases in China (Aly, Al-Alousi and Salem, 2005, Bor, Chen and Yen, 2006, Cheng, Li, You and Hu, 2005, Hu and Kitts, 2005, Jung, Richter, Kabrodt, Lucke, Schellenberg and Herrling, 2006, Kang, Yoon, Cho, Han, Lee, Park and Kim, 2005, Kim, Min, Jeong, Lee, Lee and Seo, 2005, Kim, Kim, Baek, Lee, Kim, Kwon and Lee, 2006, Kim, Oh, Kwon, Oh, Lim and Shin, 2006, Ko, Wei and Chiou, 2006, Leu, Wang, Huang and Shi, 2005, Leung, Kuo, Yang, Lin and Lee, 2006, Li, Yuan, Xiong, Lu, Qin, Chen and Liu, 2006, Li, Zhang, Zhang, Liu, Wang, Wang, Zhu and Chen, 2006, Ling, Wu and Li, 2006, Makino, Tsubouchi, Murakami, Haneda and Yoshino, 2006, Niu, Chang, Jiang, Cui, Chen, Yuan and Tu, 2006, Niu, Cui, Li, Chang, Jiang, Qiao and Tu, 2006, Rusu, Tamas, Puica, Roman and Sabadas, 2005, Seo, Koo, An, Kwon, Lim, Seo, Ryu, Moon, Kim, Kim and Hong, 2005, Son, Moon, Lee, Son, Kim, Kang, Son, Lee and Chang, 2006, Strzelecka, Bzowska, Koziel, Szuba, Dubiel, Riviera Nunez, Heinrich and Bereta, 2005, Su, 2004, Suh, Chung, Son, Kim, Moon, Son, Kim, Chang and Kim, 2006, Thanabhorn, Jaijoy, Thamaree, Ingkaninan and Panthong, 2006, Zhan and Yang, 2006. F. koreana, used as a single-agent antimicrobial, antiinflammatory, and diuretic, contains the cyclohexylethanoid compound rengyolone, found to be a potent inhibitor of NO and tissue necrosis factor-α (TNF-α) in vitro; this compound inhibits inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression in macrophages in response to lipopolysaccharide (LPS) stimulation …”